The days are getting shorter as we "fall back” into standard time and it may be affecting your mood. While we settle into our ...

Efforts have been made in recent years to clarify the value of exercise as an adjunctive or independent treatment for major ...

The following is a summary of “Voice of depression: speech features as biomarkers for major depressive disorder,” published ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to unveil promising 12-month Phase 2 data for CYB003 in treating Major Depressive ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

Clearance paves the way for the use of the TMS technology to treat patients with major depressive disorder (MDD), ...

A new digital health intervention, developed over a decade of research, uses a gamified app to help reduce depressive symptoms by disrupting ruminative thought patterns.